Phase II/III Study of Anti-VEGF in Neovascular AMD

NCT00021736 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 540

Last updated 2005-06-24

No results posted yet for this study

Summary

The purpose of the study is to determine whether the anti-VEGF drug is effective at stabilizing and/or improving vision in patients with the wet form of AMD

Conditions

  • Macular Degeneration
  • Choroidal Neovascularization

Interventions

DRUG

EYE001 anti-VEGF aptamer

Sponsors & Collaborators

  • Eyetech Pharmaceuticals

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-07-31
Completion
2002-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00021736 on ClinicalTrials.gov